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Abstract
Background: The purpose of this meta-analysis is to compare the efficacy of pancreatoduodenectomy (PD) with
extended lymphadenectomy (PD/ELND) versus standard PD in the treatment of pancreatic cancer, with the hope of
providing evidence for clinical practice.
Methods: The retrieval of relevant literature published before September 2012 was carried out on PubMed,
Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) by computer. Information was
extracted according to Cochrane systematic review methods, and analyzed using software Stata 11.0.
Results: Five prospective randomized controlled trials (RCTs) were included in this meta-analysis of 555 cases
(278 in the PD/ELND group and 277 in the standard PD group). The PD/ELND group showed a significantly
lower 3-year survival rate (relative risk (RR) = 1.46, 95% confidence interval (CI) 1.03 to approximately 2.06, P = 0.034),
prolonged operative time (weighted mean difference WMD= −1.03, 95% CI −1.96 to approximately −0.10, P = 0.029)
and higher incidence of postoperative complications (RR = 0.56, 95% CI 0.42 to approximately 0.77, P = 0.000) by
comparing with standard PD group. Besides, no significant difference was observed in the 1-year survival rate
(RR = 0.87, 95% CI 0.60 to approximately 1.25, P = 0.69), 5-year survival rate (RR = 1.04, 95% CI 0.68 to approximately
1.58, P = 0.854), postoperative mortality (RR = 1.14, 95% CI 0.43 to approximately 3.00, P = 0.789), length of stay
(WMD = −0.32, 95% CI −2.57 to approximately 1.94 , P = 0.784) and the amount of blood transfusions (WMD= −0.14,
95% CI −0.36 to approximately 0.08, P = 0.213).
Conclusions: PD/ELND does not have an advantage over standard PD in the survival rate for patients with pancreatic
cancer, but does increase operative time and incidences of postoperative complications.
Keywords: Pancreatic cancer, Pancreatoduodenectomy with extended lymphadenectomy, Standard
pancreatoduodenectomy, Meta-analysis
Background
Pancreatic cancer case about 20 million deaths worldwide
each year with an increasing incidence. Now, pancreatic
cancer has become the fourth leading cause of death
among cancers, and is one of the common gastrointestinal
malignancies. It possesses some characteristics, such as fast
progress, high degree of malignancy and early metastasis,
which eventually bring poor prognosis for patients with a
5-year survival rate of only l% to 3% [1,2]. Currently, sur-
gery is still the most basic means for treating pancreatic
cancer, also the only method of hoping for curative treat-
ment. Since the first successful implementation of surgery
in 1935 by Whipple, pancreatoduodenectomy (PD) has
been the standard operation for pancreatic cancer [3]. As
pancreatic cancer spreads to regional lymph nodes and
even to the pancreas plexus along the perineurium, efforts
to improve the surgical method have been based on
* Correspondence: xu_xinbao@sohu.com
1Department of Hepatobiliary Surgery, Airforce General Hospital of Chinese
People's Liberation Army, Beijing 100142, China
Full list of author information is available at the end of the article
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
© 2013 Xu et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Xu et al. World Journal of Surgical Oncology 2013, 11:311
http://www.wjso.com/content/11/1/311
conventional PD and variations of extended PD, such as
pancreatoduodenectomy with extended lymphadenectomy
(PD/ELND) [4].
However, the use of PD/ELND is controversial at
home and abroad. In 1973, Fortner [5] suggested that re-
gional resection should include the pancreas and the im-
mediate area of lymphatic drainage. But it was not
widely accepted because there was no solid evidence to
support this technique. However, Ishikawa [6] proposed
an improved 3-year survival rate with an extended
lymphadenectomy in 1988. Subsequently, several studies
were carried out to explore the efficacy of extended sur-
gery with conflicting conclusions. For example, Tadao
Manabe et al. showed that the survival rates in pa-
tients treated with radical operation were significantly
higher than in patients with nonradical operation [7],
and Naganuma et al. showed that extended resection
in Japan can improve the curative resection and actu-
arial survival rate compared with standard resection
[8]. In a study by Satake et al., however, no signifi-
cant difference was observed in the overall postopera-
tive cumulative survival rates between the standard
and extended operation [9].
Meta-analysis, as a statistical analysis method, can quan-
titatively pool a number of independent clinical studies
and provide some information to resolve the contro-
versial and uncertain questions. Therefore, we collected
relevant literature and performed a meta-analysis to sys-
tematically assess the clinical efficacy of PD/ELND and
standard PD and to provide evidences for the clinical ap-
plications of PD/ELND.
Methods
Literatures that compared the efficacy of PD/ELND and
standard PD in the treatment of pancreatic cancer was
retrieved through searches of PubMed, Medline, Embase
and Cochrane Central Register of Controlled Trials
(CENTRAL) by computer, and supplemented by manual
searches and reference backtracking. The deadline was
set for September 2012. The following words or terms
were adopted as keywords or key terms: pancreatic cancer,
pancreatic adenocarcinoma, pancreatoduodenectomy, pan-
creatoduodenectomy with extended lymphadenectomy,
etcetera.
Inclusion and exclusion criteria
The inclusion and exclusion criteria in this meta-analysis
were as follows: (1) English literatures published abroad
were included except for non-original literatures and re-
view literatures; (2) the objects of study should be pa-
tients with pancreatic cancer(approved by ethics committee
of the Airforce General Hospital of Chinese People's
Liberation Army; (3) prospective randomized controlled
trials (RCTs) were included whereas retrospective studies,
non-RCTs and case reports were excluded; (4) PD/ELND
was required for patients to be assigned the test group
whereas standard PD was used to assign patients to the
control group; (5) complete data were available with a spe-
cific number of cases; (6) diagnostic criteria and thera-
peutic evaluation indicators were clearly described; and
(7) at least one of the following indicators was included
(operative time, postoperative hospital stay, amount of
blood transfusions, incidence of postoperative complica-
tions, postoperative mortality, postoperative 1-, 3- and
5-year survival rate).
Data extraction
Two researchers independently assessed literatures for the
following aspects: (1) general information (first author,
publication year, source, and publication date); (2) study
design; (3) number of cases, demographic characteristics,
and treatment outcomes; and (4) conclusions.
Statistical analysis
Meta-analysis was performed using software Stata 11.0
(StataCorp LP, Texas,USA).
The standardized weighted mean difference (WMD)
with corresponding 95% confidence interval (CI) was
calculated for continuous data, while relative risk
(RR) with 95% CI was determined for dichotomous
data. The significance level was set as 0.05. Hetero-
geneity between studies was detected with a Chi-
square test before pooling data, and the quantity of
heterogeneity was measured by using the I2 statistic.
A fixed effects model was used if P >0.05 according
to test, while a random effects model was adopted if
P ≤0.05.
Additionally, to assess the influence of the trial quality
on our meta-analysis, we performed the sensitivity ana-
lysis by including only the trials that included a majority
of adult patients with pancreatic cancer.
Results
Basic information
After searching the studies by the keywords or key
terms, 90 relevant literatures were obtained after a pre-
liminary screening. Then, these literatures were further
screened according to inclusion and exclusion criteria.
Finally, five studies, Pedrazzoli et al. [10], Farnell et al.
[11], Yeo et al. [12], Riall et al. [13] and Nimura et al.
[14] were included in this meta-analysis. All five studies
were prospective RCTs with a total of 555 cases: 278 in
the PD/ELND group and 277 in the standard PD group.
They were published during the period 1998 to 2012.
Basic information such as authors, research time, coun-
try, age of patients, sex ratio, number of cases in test
group, number of cases in control group and indicators
is shown in Table 1.
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Efficacy evaluation of pancreatoduodenectomy with
extended lymphadenectomy in treatment of pancreatic
cancer
Postoperative 1-year survival rate
A total of four studies [11-14] described the 1-year survival
rate for patients with pancreatic cancer. As between-study
heterogeneity was not observed (P = 0.117, I2 = 53.3%), a
fixed effects model was used for analysis. No significant
difference was identified in 1-year survival rate between
the PD/ELND group and the standard PD group according
to the analysis result (RR = 0.87, 95% CI 0.60 to approxi-
mately 1.25, P = 0.69, Figure 1).
Postoperative 3-year survival rate
In these five published articles, four studies [11-14] re-
ported the 3-year survival rate of the patients with PD/
ELND and PD. Due to a lack of between-study hetero-
geneity (P = 0.117, I2 = 53.4%), a fixed effects model was
used for further analysis. We found that the 3-year sur-
vival rate of the standard PD group was significantly
higher than that of the PD/ELND group (RR = 1.46, 95%
CI 1.03 to approximately 2.06, P = 0.034, Figure 2).
Postoperative 5-year survival rate
The 5-year survival rate was also reported in four
studies [11-14]. Because between-study heterogeneity
was still absent in the result (P = 0.098, I2 = 56.9%), a
fixed effects model was applied in this meta-analysis.
No obvious difference was observed in 5-year survival
rate between the PD/ELND group and the standard
PD group (RR = 1.04, 95% CI 0.68 to approximately
1.58, P = 0.854, Figure 3).













Pedrazzoli et al. [10] 3/1991 to
3/1994
Italy 59.2/62 25/16 41/40 operative time, postoperative hospital stay, amount
of blood transfusions, incidence of postoperative
complications, mortality, 4-year survival rate27/13
Farnell et al. [11] 5/1997 to
7/2003
U.S. 67/66 18/21 39/40 operative time, postoperative hospital stay, incidence
of postoperative complications, mortality, 1-, 3-, and
5-year survival rate,20/20
Yeo et al. [12,13] 4/1996 to
6/2001
U.S. 65.2/66.2 76/72 148/146 operative time, postoperative hospital stay, amount of
blood transfusions, incidence of postoperative
complications, mortality, 1-, 3-, and 5-year survival rate85/61
Nimura et al. [14] 2000.3 to
2003.5
Japan 61/62 25/26 51/50 operative time, postoperative hospital stay, amount of
blood transfusions, incidence of postoperative
complications, mortality, 1-, 3-, and 5-year survival rate25/25
PD, pancreatoduodenectomy; PD/ELDN, pancreatoduodenectomy with extended lymphadenectomy.
Figure 1 Forest plot for the 1-year survival rate between the pancreatoduodenectomy with extended lymphadenectomy (PD/ELND)
group and the standard pancreatoduodenectomy (PD) group. On the left, the name of the first author of the study is followed by the
publication year. The size of the black box corresponding to each study is proportional to the sample size, and the horizontal line shows the
corresponding 95% CI of the relative risk (RR) displayed on the right.
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Incidence of postoperative complications
In all five studies [10-14], the incidence of postoperative
complications of patients with pancreatic cancer was de-
tected. The between-study heterogeneity was not ob-
served (P = 0.523, I2 = 0.0%); therefore a fixed effects
model was used for analysis. According to the meta-
analysis results (RR = 0.56, 95% CI 0.42 to approximately
0.77, P = 0.000, Figure 4), the incidence of postopera-
tive complications in PD/ELND group was signifi-
cantly higher than that in standard PD group.
Postoperative mortality
These five studies [10-14] also described the postopera-
tive mortality of patients with pancreatic cancer. Since
no between-study heterogeneity was observed (P = 0.597,
I2 = 0.0%), a fixed effects model was used for analysis.
No significant difference was identified in postopera-
tive mortality between the PD/ELND group and the
standard PD group according to the meta-analysis re-
sult (RR = 1.14, 95% CI 0.43 to approximately 3.00, P =
0.789, Figure 5).
Figure 2 Forest plot for the 3-year survival rate between the pancreatoduodenectomy with extended lymphadenectomy (PD/ELND)
group and the standard pancreatoduodenectomy (PD) group. The size of the black box corresponding to each study is proportional to the
sample size, and the horizontal line shows the corresponding 95% CI of the relative risk (RR) displayed on the right.
Figure 3 Forest plot for the 5-year survival rate between the pancreatoduodenectomy with extended lymphadenectomy (PD/ELND)
group and the standard pancreatoduodenectomy (PD) group. The size of the black box corresponding to each study is proportional to the
sample size, and the horizontal line shows the corresponding 95% CI of the relative risk (RR) displayed on the right.
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Operative time
In these five studies [10-14], the operative time of
pancreatic cancer patients with different operations
was included. A random effects model was adopted
because significant between-study heterogeneity was
shown in this analysis (P = 0.000, I2 = 99.9%). The op-
erative time of the PD/ELND group was significantly
longer than that of the standard PD group according
to the analysis (WMD= −1.03, 95% CI −1.96 to approxi-
mately −0.10, P = 0.029, Figure 6).
Amount of blood transfusions
There were four studies [10,12-14] that provided the
amount (in volume) of blood transfusions. As between-
study heterogeneity existed (P = 0.000, I2 = 98.8%), a
random effects model was used for analysis. No significant
Figure 4 Forest plot for the incidence of postoperative complications between the pancreatoduodenectomy with extended
lymphadenectomy (PD/ELND) group and the standard pancreatoduodenectomy (PD) group. The size of the black box corresponding to
each study is proportional to the sample size, and the horizontal line shows the corresponding 95% CI of the relative risk (RR) displayed on
the right.
Figure 5 Forest plot for the postoperative mortality between the pancreatoduodenectomy with extended lymphadenectomy
(PD/ELND) group and the standard pancreatoduodenectomy (PD) group. The size of the black box corresponding to each study is
proportional to the sample size, and the horizontal line shows the corresponding 95% CI of the relative risk (RR) displayed on the right.
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difference was observed between the PD/ELND group
and the standard PD group (WMD= −0.14, 95% CI −0.36
to approximately 0.08, P = 0.213, Figure 7).
Hospital stay
Finally, the hospital stays days of pancreatic cancer
patients after two different operations were reported
in these five studies [10-14]. Because between-study
heterogeneity existed (P = 0.000, I2 = 99.6%), a random
effects model was adopted for analysis. No significant
difference was observed in hospital stays between the
PD/ELND group and the standard PD group (WMD
= −0.32, 95% CI −2.57 to approximately 1.94, P = 0.784,
Figure 8).
Discussion
The advantage of PD/ELND over standard PD for the
treatment of pancreatic cancer is still controversial. To
provent the lymphatic metastasis of pancreatic cancer, a
PD/ELND, which extends the surgical region, makes
sense to avoid recurrence. However, according to several
studies, the results were not consistent. Although PD/
ELND significantly increased the resection rate, it might
fail to correspondingly improve the survival time for
Figure 6 Forest plot for the operative time between the pancreatoduodenectomy with extended lymphadenectomy (PD/ELND) group
and the standard pancreatoduodenectomy (PD) group. The size of the black box corresponding to each study is proportional to the sample
size, and the horizontal line shows the corresponding 95% CI of the relative risk (RR) displayed on the right.
Figure 7 Forest plot for the amount of blood transfusions between the pancreatoduodenectomy with extended lymphadenectomy
(PD/ELND) group and the standard pancreatoduodenectomy PD group. The size of the black box corresponding to each study is
proportional to the sample size, and the horizontal line shows the corresponding 95% CI of the relative risk (RR) displayed on the right.
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patients. In addition, PD/ELND could bring more compli-
cations, which subsequently eroded postoperative quality
of life and raised mortality [15-17].
This meta-analysis showed that PD/ELND resulted in
a significantly lower 3-year survival rate, but prolonged
operative time and resulted in a higher incidence of
postoperative complications for patients with pancreatic
cancer compared with standard PD. Additionally, no sig-
nificant difference was observed in 1- or 5-year survival
rate, postoperative mortality, hospital stay and the vol-
ume of blood transfusions between the two groups.
Many meta-analyses were performed with extended
lymphadenectomy for other malignancies, such as breast
cancer [18,19] and papillary thyroid carcinoma [20,21].
The conclusions were various, and the evidences of the
clinical improvements were rather weak. Authors stressed
that more RCTs are needed for further understanding the
feasibility of extended lymphadenectomy, which was also
appropriate for pancreatic cancer.
Studies included in this meta-analysis came from dif-
ferent countries with various ethnic groups. The random
allocation method was applied in each study, and the
basic characteristics for patients from the test group and
control group were not different, all of which guaranteed
the representativeness of the conclusion. However, there
were some limitations that need to be noted. The number
of RCTs and cases contained in this evaluation were rather
small. Moreover, variance also existed in the method of
blinding, lymph node dissection, comprehensive treatment
program after surgery and in postoperative follow-up
time. All of these factors affected the strength of evidences
and comprehensiveness of this systematic evaluation.
Therefore, more prospective RCTs with large sample sizes
and adequate follow-up times are necessary to verify the
efficacy of PD/ELND for treatment of pancreatic cancer.
Conclusions
Based upon the above statistical results, we conclude
that PD/ELND fails to gain advantages over standard PD
in the survival rate of patients with pancreatic cancer,
but may increase the operative time and the incidence of
postoperative complications.
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Figure 8 Forest plot for hospital stays between the pancreatoduodenectomy with extended lymphadenectomy (PD/ELND) group and
the standard pancreatoduodenectomy (PD) group. The size of the black box corresponding to each study is proportional to the sample size,
and the horizontal line shows the corresponding 95% CI of the relative risk (RR) displayed on the right.
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